Should you buy BioNTech stock now?
No, the technical signal for BioNTech is currently Sell. BioNTech trades at $95.73 as of Oct 7, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -0.742 with falling momentum (signal: -0.479); RSI is at 43.0 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $116.12 points to 21.3% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for BioNTech stock?
The average analyst price target for BioNTech is $116.12. The current price is $95.73, which gives an upside of 21.3%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $104.51 and $127.73.
Is BioNTech a dividend stock?
BioNTech has not paid a dividend since 2022. The latest dividend was $2.11 per share with an ex-dividend date of Jun 2, 2022.
What is the risk of BioNTech stock?
BioNTech is rated as a stock in the risk category Moderate. the annual standard deviation is 45.8%, which classifies the stock as Moderate.
Is BioNTech overvalued?
No, BioNTech is considered undervalued based on the analyst price target (21.3% upside). BioNTech has the following valuation ratios: a P/S ratio of 9.2, a P/B ratio of 1.2. The analyst price target suggests that the stock is undervalued by 21.3%.
Is BioNTech overbought?
No, BioNTech is not overbought. RSI is at 43.0 (neutral zone). The technical indicators show: RSI is at 43.0 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 2.1% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next BioNTech earnings report?
BioNTech reports its next earnings on November 3, 2026. The stock currently trades at $95.73.
Is BioNTech shorted?
Yes, BioNTech is shorted with 3.5% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying BioNTech stock?
No, insiders are not buying BioNTech shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 20 sales. On a net basis, 62,323,835 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 62,323,835 $ sold. Active sellers include Sahin Ugur. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is BioNTech a good stock?
Based on our total score, BioNTech is rated as a poor stock with a total score of 27 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 29/100, Quality: 6/100, Momentum: 48/100. In addition: analysts see 21.3% upside to the price target; technical signal: Sell. Whether BioNTech is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for BioNTech stock?
The outlook for BioNTech based on current data: the average analyst price target is $116.12 (+21.3%); the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on Nov 3, 2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is BioNTech stock falling?
BioNTech is falling right now. The technical indicators show: the price is 2.1% below the 20-day average; MACD is negative with falling momentum (bearish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can BioNTech go?
The average analyst price target for BioNTech is $116.12, which corresponds to a potential gain of 21.3% from the current price of $95.73. The stock has traded between $79.52 and $124.00 over the last 52 weeks. The price is 22.8% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can BioNTech fall?
The stock has traded as low as $79.52 over the last 52 weeks — that is 16.9% below the current price of $95.73. The biggest decline (drawdown) in the same period was 35.9% from high to low. Within a year, the price typically swings about ±45.8% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does BioNTech do?
BioNTech SE develops medicines that help the body's immune system fight cancer and infectious diseases. The company makes money by carrying out research and moving new products through clinical trials, which are the required tests that check whether a treatment is safe and eff... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate BioNTech as an investment.
Did BioNTech raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from BioNTech. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is BioNTech making money or losing money?
No, BioNTech is currently not making money — the company is losing money with a negative profit margin of -63.6%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can BioNTech go bankrupt?
The bankruptcy risk of BioNTech is rated as low. Altman Z2 (a model for assessing financial distress) is 13.64 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 16% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does BioNTech have a lot of debt?
No, BioNTech has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 16%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
